{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:01:46Z","timestamp":1758398506553},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cco.0000000000000060","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T09:35:33Z","timestamp":1390469733000},"page":"230-236","source":"Crossref","is-referenced-by-count":11,"title":["Recent advances in primary cutaneous B-cell lymphomas"],"prefix":"10.1097","volume":"26","author":[{"given":"Maarten H.","family":"Vermeer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210128","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1200\/JCO.2005.08.137","article-title":"The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry.","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"R2-15-20210128","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients.","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"R3-15-20210128","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Italian Study Group for Cutaneous LymphomasPrognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-15-20210128","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers.","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-15-20210128","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R6-15-20210128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0022-202X.2004.22720.x","article-title":"Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.","volume":"123","author":"Hallermann","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R7-15-20210128","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"R8-15-20210128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2013.07.019","article-title":"Treatment and outcomes in patients with primary cutaneous b-cell lymphoma: the BC Cancer Agency Experience.","volume":"87","author":"Hamilton","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-15-20210128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2340\/00015555-1112","article-title":"Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study.","volume":"91","author":"Hallermann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R10-15-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2230.2012.04461.x","article-title":"Characteristics of primary cutaneous lymphoma according to WHO-EORTC classification in Korea.","volume":"38","author":"Lee","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"R11-15-20210128","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1346-8138.2010.01049.x","article-title":"Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008.","volume":"38","author":"Fujita","year":"2011","journal-title":"J Dermatol"},{"key":"R12-15-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"ISCL and the EORTCTNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"R13-15-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma.","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"key":"R14-15-20210128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1365-2133.2007.08239.x","article-title":"The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group.","volume":"157","author":"Senff","year":"2007","journal-title":"Br J Dermatol"},{"key":"R15-15-20210128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428190802064925","article-title":"Primary cutaneous B-cell lymphomas: clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCLEORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.","volume":"49","author":"Golling","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R16-15-20210128","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer; International Society for Cutaneous LymphomaEuropean Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"R17-15-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/1523-1747.ep12614479","article-title":"Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects.","volume":"99","author":"Rijlaarsdam","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R18-15-20210128","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets.","volume":"34","author":"Edinger","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R19-15-20210128","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","article-title":"The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment.","volume":"112","author":"van Maldegem","year":"2008","journal-title":"Blood"},{"key":"R20-15-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2559.1993.tb00469.x","article-title":"Cutaneous immunocytomas: a clinicopathologic study of 26 cases.","volume":"23","author":"Rijlaarsdam","year":"1993","journal-title":"Histopathology"},{"key":"R21-15-20210128","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/modpathol.2013.106","article-title":"Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression.","volume":"26","author":"Brenner","year":"2013","journal-title":"Mod Pathol"},{"key":"R22-15-20210128","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Dutch Cutaneous Lymphoma GroupResults of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification.","volume":"143","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"R23-15-20210128","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases.","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"R24-15-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2008.04.012","article-title":"Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome in primary cutaneous marginal zone lymphoma.","volume":"59","author":"Gerami","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R25-15-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.","volume":"69","author":"Servitje","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R26-15-20210128","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"R27-15-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","article-title":"Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma.","volume":"24","author":"Dijkman","year":"2006","journal-title":"J Clin Oncol"},{"key":"R28-15-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-15-20210128","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.","volume":"59","author":"Morales","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R30-15-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"key":"R31-15-20210128","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2340\/00015555-1113","article-title":"Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.","volume":"91","author":"Quereux","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R32-15-20210128","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br J Dermatol"},{"key":"R33-15-20210128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.","volume":"167","author":"Penate","year":"2012","journal-title":"Br J Dermatol"},{"key":"R34-15-20210128","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/PAS.0b013e3181e5060a","article-title":"IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma.","volume":"34","author":"Koens","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R35-15-20210128","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood-2005-08-3443","article-title":"Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.","volume":"107","author":"Dijkman","year":"2006","journal-title":"Blood"},{"key":"R37-15-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/jid.2008.357","article-title":"Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type.","volume":"129","author":"Senff","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R38-15-20210128","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"R39-15-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","article-title":"Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.","volume":"145","author":"Grange","year":"2009","journal-title":"Arch Dermatol"},{"key":"R40-15-20210128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab.","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R41-15-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas: an applicational observation.","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br J Dermatol"},{"key":"R42-15-20210128","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"R43-15-20210128","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/jid.2012.102","article-title":"MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.","volume":"132","author":"Pham-Ledard","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R44-15-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jid.2013.265","article-title":"Nuclear factor-B pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.","volume":"134","author":"Koens","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R45-15-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma.","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"R46-15-20210128","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-B in lymphoid malignancies.","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol Rev"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:42Z","timestamp":1620950142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201403000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000060","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}